WO2022170405A1 - Composition pharmaceutique aqueuse à base d'hyaluronate de sodium sous forme de pulvérisation nasale - Google Patents

Composition pharmaceutique aqueuse à base d'hyaluronate de sodium sous forme de pulvérisation nasale Download PDF

Info

Publication number
WO2022170405A1
WO2022170405A1 PCT/BR2021/050068 BR2021050068W WO2022170405A1 WO 2022170405 A1 WO2022170405 A1 WO 2022170405A1 BR 2021050068 W BR2021050068 W BR 2021050068W WO 2022170405 A1 WO2022170405 A1 WO 2022170405A1
Authority
WO
WIPO (PCT)
Prior art keywords
sodium hyaluronate
pharmaceutical composition
aqueous sodium
nasal spray
spray
Prior art date
Application number
PCT/BR2021/050068
Other languages
English (en)
Portuguese (pt)
Inventor
Alírio Oliveira Da Silva FILHO
Jorge Antonio SASSONE
Original Assignee
Master Indústria E Comércio De Produtos Odontológicos E Farmacêuticos Ltda Me
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Master Indústria E Comércio De Produtos Odontológicos E Farmacêuticos Ltda Me filed Critical Master Indústria E Comércio De Produtos Odontológicos E Farmacêuticos Ltda Me
Priority to PCT/BR2021/050068 priority Critical patent/WO2022170405A1/fr
Publication of WO2022170405A1 publication Critical patent/WO2022170405A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants

Definitions

  • the present invention relates to an innovative pharmaceutical composition, which consists of a Sodium Hyaluronate nasal spray, which relieves dryness and irritation of the nostrils caused by aging, low humidity, colds, congestion or medication side effects.
  • nasal epithelial cells Under certain conditions the ability of nasal epithelial cells to secrete mucus, preserve moisture and filter air may be impaired. Conditions such as low humidity, aging, side effects of medications used to treat allergies, common colds or acne result in dryness of the nose and crust buildup causing discomfort, pain, nosebleeds and coughing.
  • Nasal inhalation as a route of drug administration is restricted to the treatment of processes that take place locally, in the upper airways, such as, for example, different cases of rhinitis.
  • the respiratory tree can be divided into three well-differentiated zones:
  • Nasopharyngeal Region It is the upper respiratory tract, which comprises the nose, mouth, pharynx and larynx.
  • Tracheobronchial Region Includes the trachea, bronchi, and terminal bronchioles.
  • Pulmonary or respiratory region corresponds to the respiratory bronchioles, the alveolar canal, the alveolar sacs and the alveoli. This region is where gas exchange takes place.
  • the factors that condition the transit of nasal medications in spray form are the size of particles or droplets, the breathing mode, the anatomical characteristics of the airways and possible pathological factors, among others. Depending on the size of particles or droplets, these are deposited in the different regions seen above. We can thus make the following differentiation, also shown in Figure 2:
  • Patent number 20050164979 Pharmaceutical composition for ophthalmological and rhinological application describes a pharmaceutical composition that contains at least panthenol and/or pantothenic acid and hyaluronic acid and/or hyaluronate and, optionally, additional pharmaceutical auxiliary agents.
  • the invention also relates to the use of the pharmaceutical composition for the treatment of ophthalmological and/or rhinological functional defects, failing to mention droplet size and physicochemical properties of the composition so that it has an exclusive action on the nostrils.
  • Patent number W02003049747 - Synergistic pharmaceutical composition for treating ophthalmological and/or rhinological dysfunction, containing panthenol or pantothenic acid and hyaluronic acid or hyaluronate) presents a pharmaceutical composition containing panthenol and/or pantothenic acid, hyaluronic acid and/or hyaluronate and optionally additional pharmaceutical aids in the treatment of ophthalmological and/or rhinological dysfunction, specifically rhinological dysfunction associated with dryness of the nasal mucosa, especially chronic rhinitis and/or rhinitis sicca, presenting the advantage of the combination of panthenol and hyaluranate that produces a synergistic effect in the treatment of both ophthalmological disorders and rhinological disorders, for example, healing of lesions in the nasal mucosa and improvement of moisture retention.
  • the inventors have developed an innovative composition, which consists of a nasal spray of Sodium Hyaluronate, which relieves dryness and irritation of the nostrils caused by aging, low humidity, colds, congestion or side effects of medicines.
  • the Sodium Hyaluronate Nasal Spray of the present invention was developed to act at the level of the Nasopharyngeal region, with the Sodium Hyaluronate adhering to the nasal mucous membrane and moisturizing it, thus preventing its dryness. Dryness of the nasal mucosa is also produced by environmental factors such as heat, air conditioning, wind and sun. Nasal dryness prevents the mucosa from fulfilling its function of wetting and cleaning the air we breathe, leaving the nostrils exposed to the invasion of pathogens. Intensive hydration with Sodium Hyaluronate maintains a protective layer on the nasal mucosa and strengthens the resistance of the nostrils against exogenous invasions.
  • the pharmaceutical composition of aqueous Sodium Hyaluronate in nasal spray form of the present invention was developed as a formulation in true aqueous solution, specifically balanced in viscosity and density, so that, when administered through a specific actuator, it produces a particular and constant spray plume pattern and Gaussian droplet size distribution where 100% of the droplets are greater than 10 microns , thus ensuring greater effectiveness in local nasal topical treatment without going beyond the nasopharyngeal region.
  • FIG. 1 Figure 1 - scheme showing the regions of the respiratory system, with emphasis on the nasopharyngeal, tracheobronchial and respiratory regions.
  • FIG. 1 Figure 2 - diagram showing the relationship between spray particle diameter and maximum level of penetration in each of the regions of the respiratory system.
  • Figure 3 Individual results of the mass test of each actuation, or pumping, or pressing.
  • Figure 4 Individual results of the droplet size distribution test by laser diffraction measured at a distance of 3 cm from the nozzle to the measurement plane.
  • Figure 5 Individual results of the droplet size distribution test by laser diffraction measured at a distance of 6 cm from the nozzle to the measurement plane.
  • a system consisting of an aqueous solution was chosen, for spray application, forming a liquid discharge aerosol, without propellant, with mechanical pressurization (actuator) with droplets of size well above 10 microns, which ensures limited action on the nostrils, protecting and strengthening the nasal mucous membrane.
  • actuator mechanical pressurization
  • this invention sought the optimal relationship between the particular Spray System chosen and the liquid formulation as a true solution in order to comply with ANVISA Normative Instruction No. 2019 that deals specifically with Nasal Sprays, and arriving at the results presented in the “RESULTS OF STUDY” section to a FEATHER Spray Standard.
  • the inventors of the present invention determined that the viscosity of the aqueous solution used has a fundamental role in obtaining the characteristics of the Spray Pattern sought and, mainly, in the droplet size. desired, i.e. 100% droplets larger than 10 microns, to avoid inadequate penetration of the product into the aforementioned tracheobronchial and/or respiratory tracts.
  • the viscosity of the solution proposed by this invention is strongly influenced by the concentration of Sodium Hyaluronate, and, additionally, by the concentration of Dexpanthenol.
  • the inventors of the present invention have obtained intermediate or high molecular weight Hyaluranates, preferably high molecular weight Hyaluranates at low concentration in the final composition, and even more preferably a combination of intermediate molecular weight Hyaluranates and high so that the final concentration of Hyaluronate in the composition is not less than 0.005% weight/volume of Hyaluronate.
  • the composition uses hyaluronic acid or its sodium salt, sodium hyaluronate, as the natural active ingredient capable of producing a pronounced hydration and coating effect on the nasal mucosa.
  • Hyaluronic acid or its sodium salt is produced according to the microorganism fermentation method and consists of a linear polysaccharide polymer where the repeating unit is a disaccharide of D-Glucuronic acid and D-Glucosamine.
  • the purity of sodium hyaluronate is a minimum of 92% W/W, with a maximum moisture content of 10% W/W; it is a hygroscopic substance.
  • the molecular weight range of sodium hyaluronate used in the present Nasal Spray composition is from 850,000 Daltons to 1,600,000 Daltons, combination of intermediate and high molecular weights.
  • the concentration of hyaluronic acid or its sodium salt used in the Nasal Spray is in the range of 0.020% W/V to 0.050% W/V, even more preferably between 0.040% W/V and 0.045% W/V and preferably 0.040% W/V. v.
  • Higher concentrations of Sodium Hyaluronate could increase the viscosity of the system whose main result would be the total deformation of the Spray Pattern sought with Dmax/Dmin values » 1 ,12. It should be noted that the Spray-PLUMA Standard is very important for all Sprays as it shows the efficiency of product entry into the nasal cavities, without the need to introduce the applicator pump tip into them.
  • Dexpanthenol at 1.0% P/V helps to obtain the correct Viscosity needed to obtain both the Spray Pattern and the desired droplet size distribution.
  • a concentration of dexpanthenol greater or less than the concentration of 1.0% W/V would result in the same effect mentioned above for Sodium Hyaluronate.
  • concentrations greater than 1% P/V can also cause an increase in the final density of the Spray, and the latter, as we will see below, also strongly influences the Spray Pattern and Droplet Size Distribution of the product.
  • the inventors of the present invention determined that the density (in g/ml at 25°C) of the aqueous solution strongly influences the characteristics of the Spray Pattern sought and, mainly , the desired droplet size, i.e. 100% droplets larger than 10 microns, to avoid inadequate penetration of the product into the aforementioned tracheobronchial and/or respiratory tract.
  • the density of the product of the present invention is mainly influenced by the concentrations of Dexpanthenol and the pH Regulating System Dibasic Sodium Phosphate Anhydrous and Monobasic Sodium Phosphate Anhydrous.
  • concentrations chosen for each of these components of the formulation were balanced in order to stay within the allowable range of densities of the final product compatible with the PLUMA Spray Standard and the Gaussian-type droplet size distribution with 100% of the droplets containing a size greater than 10 microns.
  • Sodium Hyaluronate is the active hydration agent of the nasal mucosa and an agent for obtaining an optimal viscosity
  • Dexpanthenol assists in said hydration, in the relief of any epithelial wound, also acting in the control of the viscosity and density of the formulation in order to obtain an optimal spray effect with the chosen Spray Pump applicator.
  • the Viscosity and Density required to obtain a constant and Elliptical Plume Spray Pattern with Dmax/Dmin from 1.00 to 1.12 to 3 and 6 cm of distance, with 100% of the Droplets larger than 10 microns and in Spray distribution must meet the following specifications:
  • the pH (7.0 - 7.5) and physiological isotonicity are provided by the pH Regulator Monobasic Sodium Phosphate/Dibasic Sodium Phosphate. This system also strongly controls the density of the final product. To preserve the sterility of the product throughout its use, the classic Benzalkonium Chloride/EDTA antimicrobial system is used in nasal preparations. This formulation allows for continuous wetting of the nostrils, relief from nasal congestion, and lacks irritating effects.
  • the content should range from 0.038% to 0.042% W/V of Sodium Hyaluronate.
  • the density should range from 1.015 to 1.025 g/ml at 25°C by the pycnometry method. Brookfield viscosity at 25°C, Spindle 1 , 100 rpm should range from 4.0 to 5.0 cps.
  • the liquid content should vary between 32 to 34 ml/vial.
  • the pH should be between 7.0 and 7.5.
  • the flow for each actuation must vary between 0.054 to 0.058 ml/pump.
  • the product must pass the sterility test.
  • Droplet size distribution assay by laser diffraction measured at a distance of 3 cm from the nozzle to the measurement plane
  • REPLACEMENT SHEETS (RULE 26) [047] This test was performed on 10 vials of the composition manufactured according to example 1; each one of them was initially activated 1 time and the measurement called START was performed on the spray launched; then the bottle was activated without interruption until reaching the final content, where the final pump was carried out, whose spray released was measured again, called FIM.
  • the laser beam diffractor performed the reading of the droplet size distribution results at a distance of 3 cm, which have a direct relationship with the formulation of example 1 and the peculiar spray system used. The result is expressed as a percentage of droplets that have a certain size expressed in microns. So, for example, choose:
  • DV (10) indicates that 10% by volume of the droplets has a size equal to or smaller than that reported in the result, in microns.
  • Dv (10) and Dv (90) together delimit the lower and upper limits of droplet size comprising 80% of the distribution centered on the mean Dv (50) with 40% for each side; the remaining 20% of the distribution is, 10% below the Dv value (10), and 10% above the value Dv (90).
  • 10% that are below Dv (10) as mentioned before, looking at the individual distribution of each vial, it is easy to understand that, in all cases, there is no droplet size equal to or less than 10 microns.
  • Droplet size distribution assay by laser diffraction measured at a distance of 6 cm from the nozzle to the measurement plane

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Otolaryngology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne une composition pharmaceutique aqueuse à base d'hyaluronate de sodium sous forme de pulvérisation nasale soulageant et aidant en cas de sécheresse et d'irritation des narines causées par le vieillissement, hydratant et humidifiant toute la narine, ainsi que par la faible humidité, les refroidissements, la congestion ou les effets secondaires de médicaments. Cette composition se présente sous la forme d'une formulation en solution aqueuse véritable, spécifiquement équilibrée en viscosité et densité, de sorte que, lors de son administration au moyen d'un actionneur spécifique, un panache de pulvérisation standard particulier et constant est obtenu, de même qu'une distribution de taille des gouttelettes gaussienne, 100% des gouttelettes étant supérieures à 10 micromètres, d'où une plus grande efficacité dans le traitement topique local nasal sans dépasser la région naso-pharyngée.
PCT/BR2021/050068 2021-02-12 2021-02-12 Composition pharmaceutique aqueuse à base d'hyaluronate de sodium sous forme de pulvérisation nasale WO2022170405A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/BR2021/050068 WO2022170405A1 (fr) 2021-02-12 2021-02-12 Composition pharmaceutique aqueuse à base d'hyaluronate de sodium sous forme de pulvérisation nasale

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/BR2021/050068 WO2022170405A1 (fr) 2021-02-12 2021-02-12 Composition pharmaceutique aqueuse à base d'hyaluronate de sodium sous forme de pulvérisation nasale

Publications (1)

Publication Number Publication Date
WO2022170405A1 true WO2022170405A1 (fr) 2022-08-18

Family

ID=82838180

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/BR2021/050068 WO2022170405A1 (fr) 2021-02-12 2021-02-12 Composition pharmaceutique aqueuse à base d'hyaluronate de sodium sous forme de pulvérisation nasale

Country Status (1)

Country Link
WO (1) WO2022170405A1 (fr)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102579478A (zh) * 2012-03-30 2012-07-18 济南康众医药科技开发有限公司 玻璃酸钠在制备药物中的应用
WO2013009519A2 (fr) * 2011-07-12 2013-01-17 Aihol Corporation Matériaux pour traiter et prévenir une maladie liée aux muqueuses
CN108066401A (zh) * 2018-01-04 2018-05-25 蓝栋林 一种用于治疗鼻炎的药物
WO2019025040A1 (fr) * 2017-07-31 2019-02-07 Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh Composition pour application nasale
WO2019125330A2 (fr) * 2017-08-10 2019-06-27 Eli̇xi̇r İlaç Araştirma Ve Geli̇şti̇rme A.Ş. Compositions de décongestionnant nasal comprenant du dexpanthénol et du hyaluronate de sodium
WO2020053783A1 (fr) * 2018-09-12 2020-03-19 Neilos S.r.l. Composition destinée à être utilisée dans la prévention et/ou le traitement de l'épistaxis

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013009519A2 (fr) * 2011-07-12 2013-01-17 Aihol Corporation Matériaux pour traiter et prévenir une maladie liée aux muqueuses
CN102579478A (zh) * 2012-03-30 2012-07-18 济南康众医药科技开发有限公司 玻璃酸钠在制备药物中的应用
WO2019025040A1 (fr) * 2017-07-31 2019-02-07 Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh Composition pour application nasale
WO2019125330A2 (fr) * 2017-08-10 2019-06-27 Eli̇xi̇r İlaç Araştirma Ve Geli̇şti̇rme A.Ş. Compositions de décongestionnant nasal comprenant du dexpanthénol et du hyaluronate de sodium
CN108066401A (zh) * 2018-01-04 2018-05-25 蓝栋林 一种用于治疗鼻炎的药物
WO2020053783A1 (fr) * 2018-09-12 2020-03-19 Neilos S.r.l. Composition destinée à être utilisée dans la prévention et/ou le traitement de l'épistaxis

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GOUTEVA INA, SHAH-HOSSEINI KIJA, MEISER PETER: "Clinical Efficacy of a Spray Containing Hyaluronic Acid and Dexpanthenol after Surgery in the Nasal Cavity (Septoplasty, Simple Ethmoid Sinus Surgery, and Turbinate Surgery)", JOURNAL OF ALLERGY, vol. 2014, 1 July 2014 (2014-07-01), pages 1 - 10, XP055880503, ISSN: 1687-9783, DOI: 10.1155/2014/635490 *

Similar Documents

Publication Publication Date Title
EP0734249B3 (fr) Nouvelle formulation amelioree d'aminoglucoside pour administration sous forme d'aerosol
JP4913595B2 (ja) 肺疾患を治療するための粘液活性剤
EP1207912A1 (fr) Antiseptiques, anti-inflammatoires et decongestionnants en aerosol pour le traitement de la sinusite
EP1420760A2 (fr) Decongestionant sous forme d'aerosol pour le traitement de sinusite
BR112015018252B1 (pt) Composição farmacêutica aquosa de dose fixa estável para administração nasal para um ser humano
BRPI9906372B1 (pt) Composição farmaceutica aquosa para aplicação na mucosa
BRPI0609924A2 (pt) uso de uma formulação em aerossol contendo cerca de 0,5 a 20% (peso/peso) de um sal selecionado do grupo consistindo em um sal de magnésio, um sal de cálcio, um sal de alumìnio, um sal de silìcio, um sal de escándio, um sal de titánio, um sal de vanádio, um sal de cromo, um sal de cobalto, um sal de nìquel, um sal de cobre, um sal de manganês, um sal de zinco, um sal de estanho, e uma combinação dos mesmos, e composição farmacêutica
US9861647B2 (en) Calcium glycerophosphate for treating and preventing respiratory diseases or conditions
ES2860098T3 (es) Composición para la aplicación nasal
PT92188B (pt) Processo para a preparacao de uma solucao aquosa contendo acido cromoglicico e salbutamol
WO2022170405A1 (fr) Composition pharmaceutique aqueuse à base d'hyaluronate de sodium sous forme de pulvérisation nasale
BR102019025446A2 (pt) Composição farmacêutica de hialuronato de sódio aquosa em forma de spray nasal
DK175032B1 (da) Farmaceutiske præparater omfattende en vandig opløsning af et pyranoquinolinderivat
ES2437690B1 (es) Formulaciones inhalatorias en forma de soluciones o de polvos secos, para la eliminación de las secreciones mucosas del aparato respiratorio
ITMI20101440A1 (it) Formulazioni inalatorie in forma di soluzioni o polveri secche, per la rimozione delle secrezioni mucose dall'apparato respiratorio
CA2701388C (fr) Glycerophosphate de calcium pour le traitement et la prevention de maladies ou de pathologies respiratoires
Rubin et al. Mucus-controlling drug therapy
Malekar et al. In-situ nasal gel: a review
CN117693352A (zh) 针对气道疾病的谷胱甘肽c4
Daviskas et al. Drug therapies that augment airway surface liquid
TW505517B (en) Novel pharmaceutical compositions of uridine triphosphate
WO2023193075A1 (fr) Composition en spray nasal bioadhésif, procédé de préparation et utilisation
US20230277424A1 (en) Treatment composition for nasal and oral dryness, nosebleeds, and allergy symptoms
BR112020016817A2 (pt) Método para tratar sintomas associados à rinite alérgica, método para fornecer um início de ação mais rápido para alívio da rinite alérgica e método para tratar um sujeito humano pediátrico que sofre de rinite alérgica
CN114073684A (zh) 三苯乙酸维兰特罗吸入溶液及其制备方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21925121

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21925121

Country of ref document: EP

Kind code of ref document: A1